Enanta Pharmaceuticals Inc (NASDAQ: ENTA) kicked off on Friday, down -5.54% from the previous trading day, before settling in for the closing price of $13.35. Over the past 52 weeks, ENTA has traded in a range of $4.09-$17.15.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -16.17%. While this was happening, its average annual earnings per share was recorded 24.68%. With a float of $27.42 million, this company’s outstanding shares have now reached $28.86 million.
Enanta Pharmaceuticals Inc (ENTA) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Enanta Pharmaceuticals Inc is 5.01%, while institutional ownership is 71.02%. The most recent insider transaction that took place on Dec 05 ’25, was worth 4,596. In this transaction an insider of this company sold 323 shares at a rate of $14.23, taking the stock ownership to the 8,377 shares. Before that another transaction happened on Dec 05 ’25, when Company’s insider sold 542 for $14.23, making the entire transaction worth $7,713. This insider now owns 16,348 shares in total.
Enanta Pharmaceuticals Inc (ENTA) Latest Financial update
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -1.05 earnings per share (EPS), higher than consensus estimate (set at -1.35) by 0.3. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.77 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 24.68% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 17.58% during the next five years compared to -16.17% drop over the previous five years of trading.
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Trading Performance Indicators
Take a look at Enanta Pharmaceuticals Inc’s (ENTA) current performance indicators. Last quarter, stock had a quick ratio of 4.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.57.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.84, a number that is poised to hit -0.77 in the next quarter and is forecasted to reach -2.26 in one year’s time.
